CEFAZOLIN- cefazolin sodium injection, powder, lyophilized, for solution

CEFAZOLIN by

Drug Labeling and Warnings

CEFAZOLIN by is a Prescription medication manufactured, distributed, or labeled by Samson Medical Technologies, L.L.C., ACS Dobfar S.p.A.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin and other antibacterial drugs, cefazolin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Cefazolin for Injection is indicated for the treatment of the following infections when caused by susceptible bacteria.

    1.1 Respiratory Tract Infections

    Respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus and Streptococcus pyogenes.

    Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.

    Cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available.

    1.2 Urinary Tract Infections

    Urinary tract infections due to Escherichia coli and Proteus mirabilis.

    1.3 Skin and Skin Structure Infections

    Skin and skin structure infections due to S. aureus, S. pyogenes, and Streptococcus agalactiae.

    1.4 Biliary Tract Infections

    Biliary infections due to E. coli, various isolates of streptococci, P. mirabilis, and S. aureus.

    1.5 Bone and Joint Infections

    Bone and joint infections due to S. aureus.

    1.6 Genital Infections

    Genital infections due to E. coli and P. mirabilis.

    1.7 Septicemia

    Septicemia due to S. pneumoniae, S. aureus, P. mirabilis, and E. coli.

    1.8 Endocarditis

    Endocarditis due to S. aureus and S. pyogenes.

    1.9 Perioperative Prophylaxis

    The prophylactic administration of cefazolin preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones).

    The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty).

    If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.

  • 2 DOSAGE AND ADMINISTRATION

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 250 mg dose of Cefazolin.

    THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION WITH STERILE WATER FOR INJECTION, USP TO A CONCENTRATION OF 100 mg per mL AND FURTHER DILUTION IN 50 mL OF A COMPATIBLE SOLUTION.

    THIS IS A PHARMACY BULK PACKAGE - NOT FOR DIRECT INJECTION

    2.1 Adult Population

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 250 mg dose of Cefazolin.

    Cefazolin for Injection should be reconstituted with Sterile Water for Injection, USP to a concentration of 100 mg per mL and further diluted in 50 mL of a compatible solution. The recommended adult dosages are outlined in Table 1. Cefazolin for Injection should be administered intravenously (IV) over approximately 30 minutes.

    Table 1: Recommended Dosing Schedule in Adult Patients with CrCl Greater Than or Equal to 55 mL/min.

    *In rare instances, doses up to 12 grams of cefazolin per day have been used.
    Site and Type of InfectionDoseFrequency
    Moderate to severe infections500 mg to 1gramEvery 6 to 8 hours
    Mild infections caused by susceptible gram-positive cocci250 mg to
    500 mg    		Every 8 hours
    Acute, uncomplicated urinary tract infections1 gramEvery 12 hours
    Pneumococcal pneumonia500 mgEvery 12 hours
    Severe, life- threatening infections (e.g., endocarditis, septicemia)*1 gram to
    1.5 grams    		Every 6 hours

    2.2 Perioperative Prophylactic Use

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 250 mg dose of cefazolin.

    To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are:

    • 1 gram to 2 grams I.V. administered ½ hour to 1 hour prior to the start of surgery.
    • For lengthy operative procedures (e.g., 2 hours or more), 500 mg to 1 gram I.V. during surgery (administration modified depending on the duration of the operative procedure).
    • 500 mg to 1 gram I.V. every 6 to 8 hours for 24 hours postoperatively.

    It is important that (i) the preoperative dose be given just (½ to 1 hour) prior to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin may be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms. The prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.

    2.3 Patients with Renal Impairment

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients with renal impairment who require less than a 250 mg dose of cefazolin. Cefazolin may be used in patients with renal impairment with the dosage adjustments outlined in Table 2. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection.

    Table 2: Dosage Adjustment for Patients with Renal Impairment
    Creatinine ClearanceDoseFrequency
    55 mL/minute or greaterFull doseNormal frequency
    35 to 54 mL/minuteFull doseEvery 8 hours or longer
    11 to 34 mL/minute½ usual doseEvery 12 hours
    10 mL/minute or less½ usual doseEvery 18 to 24 hours

    2.4 Preparation for Use of Cefazolin for Injection, USP bag SmartPak® Pharmacy Bulk Package

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 250 mg dose of cefazolin.

    Directions for Proper Use of a Pharmacy Bulk Package

    • NOT FOR DIRECT INFUSION. The Pharmacy Bulk Package is for use in the hospital pharmacy admixture service only in a suitable work area, such as a laminar flow hood. Using aseptic technique, the container closure may be penetrated only one time after reconstitution using a suitable sterile dispensing set or transfer device that allows measured dispensing of the contents. Use of a syringe and needle is not recommended as it may cause leakage. The withdrawal of container contents should be accomplished without delay. However, should this not be possible, a maximum time of 4 HOURS from initial reconstitution port closure entry is permitted to complete fluid transfer operations. This time limit should begin with the introduction of the solvent or diluent into the Pharmacy Bulk Package. Discard any unused portion after 4 HOURS. This pharmacy bulk package is not intended to be dispensed as a unit.
    • PRIOR TO RECONSTITUTION: Visually examine outer (natural foil) bag for damage. IF THE SEAL IS BROKEN OR DAMAGE IS OBSERVED, DO NOT OPEN THE OUTER BAG. STERILITY OF THE INNER BAG SURFACE MAY BE COMPROMISED. DISCARD BOTH BAGS IMMEDIATELY. DO NOT USE THE INNER BAG IF PARTICULATE OR FOREIGN MATTER IS PRESENT, IF THE DRY POWDER IS DARK YELLOW OR BROWN, IF THE SEALS ARE NOT INTACT, OR IF THERE IS ANY OTHER DAMAGE TO THE BAG. IN SUCH CASES, DISCARD THE BAG IMMEDIATELY.
    • After initial reconstitution port entry, use entire contents of the Pharmacy Bulk Package promptly. Any unused portion must be discarded after 4 HOURS.
    • Gather the following items prior to the reconstitution of the product: Appropriate number of bags of Sterile Water for Injection and, depending upon the method of filling, appropriate sterile tubing and adapters.

    INSTRUCTION FOR RECONSTITUTION OF THE PHARMACY BULK PACKAGE BAG SmartPak®

    The entire contents of the bag and the preparation process (reconstitution and dilution) should be completed within 4 hours of initial entry.

    Figure

    • Document the date and time reconstitution starts in the designated place on the container label. The entire contents of the bag must be used within 4 hours from the time of initial entry.
    • Remove the translucent unthreaded cap from the reconstitution (smaller) port and discard it.
    • Reconstitute the powder through the reconstitution (smaller) port, using Sterile Water for Injection according to the table below
    Reconstitution Table
    SmartPak® Bag SizeAmount of Sterile WaterApproximate Concentration
    100 grams960 mL100 mg/mL (1 g/10 mL)
    300 grams2880 mL100 mg/mL (1 g/10 mL)

    • After reconstitution is complete, remove the transfer needle from the reconstitution port.
    • Place the bag on a flat surface of a laminar flow hood and mix for at least 15 minutes for the 100 gram product or 25 minutes for the 300 gram product by rocking gently from side to side. CAUTION: To avoid possible leakage caused by the heavy weight of the added water, do not shake vigorously or pull strongly on the bag.
    • When foam dissipates, visually inspect the bag to verify the solution is clear, colorless to pale yellow and free of particulate matter. DO NOT USE THE INNER BAG IF PARTICULATE OR FOREIGN MATTER IS PRESENT.
    • Unscrew the clear threaded cap from the transfer (larger) port and discard it. Attach sterile tubing and filling adapter unit to the transfer port.
    • Reconstituted solution can now be transferred using the transfer port and the filling adapter.

    It should be noted that the spike placed into the transfer port of the Pharmacy Bulk Package SmartPak® is NEVER removed during this procedure and that the reconstitution port is self-sealing.

    Dilution

    • Hang the bag from two eyelets.
    • Following reconstitution, transfer 10 mL of the reconstituted solution into transfusion bags, each containing 50 mL of one of the compatible solutions below.

    Compatible solutions for dilution are the following:

             Sodium Chloride Injection, USP
             5% Detrose Injection, USP

    • Dilution should be completed within the 4 hour preparation process.
    • When diluted according to the instructions above, cefazolin is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C or 41°F).

    Administration

    Prior to administration, parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit.

  • 3 DOSAGE FORMS AND STRENGTHS

    • 100 grams Cefazolin for Injection, USP, Pharmacy Bulk Package bag SmartPak®
    • 300 grams Cefazolin for Injection, USP, Pharmacy Bulk Package bag SmartPak®

    THIS IS A PHARMACY BULK PACKAGE – NOT FOR DIRECT INJECTION

  • 4 CONTRAINDICATIONS

    4.1 Hypersensitivity to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins or Other Beta-lactams

    Cefazolin for Injection, USP is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins or other beta-lactams [see Warnings and Precautions (5.1)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins or Other Beta-lactams

    Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin for Injection, USP is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or carbapenems. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin for Injection, USP occurs, discontinue the drug.

    5.2 Use in Patients with Renal Impairment

    Cefazolin for Injection USP – Pharmacy Bulk Package bags SmartPak® should not be used in renally impaired patients who require less than a 250 mg dose of cefazolin.

    As with other beta-lactam antibacterial drugs, seizures may occur if inappropriately high doses are administered to patients with impaired renal function (creatinine clearance less than 55 mL/minute) [see Dosage and Administration (2.3)].

    5.3 Clostridium difficile-associated Diarrhea

    Clostridium difficile associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including cefazolin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin- producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    5.4 Risk of Development of Drug-resistant Bacteria

    Prescribing Cefazolin for Injection, USP in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    As with other antimicrobials, prolonged use of Cefazolin for Injection, USP may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.

    5.5 Drug/Laboratory Test Interactions

    Urinary Glucose

    The administration of cefazolin may result in a false-positive reaction with glucose in the urine when using CLINITEST® tablets. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (e.g., CLINISTIX®) be used.

    Coombs' Test

    Positive direct Coombs tests have been reported during treatment with cefazolin, In hematologic studies or in transfusion-cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions to cefazolin are described below and elsewhere in the labeling:

    • Hypersensitivity reactions [See Warnings and Precautions (5.1)]
    • Clostridium difficile-associated diarrhea [see Warnings and Precautions (5.3)]

    6.1 Clinical Trials Experience

    The following adverse reactions were reported from clinical trials:

    Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia, and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see Warnings and Precautions (5.3)].

    Allergic: Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome.

    Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia.

    Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received.

    Renal: As with other cephalosporins, reports of increased BUN and creatinine levels, as well as renal failure, have been received.

    Local Reactions: Instances of phlebitis have been reported at site of injection. Some induration has occurred.

    Other Reactions: Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis). Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.

    6.2 Cephalosporin-class Adverse Reactions

    In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal impairment, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, hepatic impairment including cholestasis and pancytopenia.

  • 7 DRUG INTERACTIONS

    Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category B.

    Reproduction studies have been performed in rats, mice, and rabbits at doses of 2000, 4000 and 240 mg/kg/day or 1-3 times the maximum recommended human dose on a body surface area basis. There was no evidence of impaired fertility or harm to the fetus due to cefazolin.

    8.2 Labor and Delivery

    When cefazolin has been administered prior to caesarean section, drug concentrations in cord blood have been approximately one quarter to one third of maternal drug levels. The drug appears to have no adverse effect on the fetus.

    8.3 Nursing Mothers

    Cefazolin is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when cefazolin is administered to a nursing woman.

    8.4 Pediatric Use

    Cefazolin for Injection USP, Pharmacy Bulk Package bag, SmartPak® should not be used in pediatric patients who require less than a 250 mg adult of cefazolin.

    8.5 Geriatric Use

    Of the 920 subjects who received cefazolin in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].

    8.6 Patients with Renal Impairment

    Cefazolin for Injection USP, Pharmacy Bulk Package bag, SmartPak® should not be used in patients with renal impairment who require less than a 250 mg dose of Cefazolin. When cefazolin is administered to patients with low urinary output because of impaired renal function (creatinine clearance less than 55 mL/minute), lower daily dosage is required [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].

  • 11 DESCRIPTION

    Cefazolin for Injection USP, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 250 mg dose of cefazolin.

    Cefazolin for Injection, USP, is a sterile, lyophilized, semisynthetic cephalosporin for intravenous administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7- [2-(1H -tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid. Each Pharmacy Bulk Package contains 48 mg (2.1 mEq) of sodium per 1 gram of cefazolin sodium. Cefazolin for Injection, USP, is supplied in 100 grams and 300 grams SmartPak® Pharmacy Bulk Packages bags equivalent. Each SmartPak® Pharmacy Bulk Package bag contains cefazolin sodium equivalent to 100 grams or 300 grams of cefazolin.

    BEFORE ADMINISTRATION, THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION USING STERILE WATER FOR INJECTION, USP TO A CONCENTRATION OF 100 mg per mL AND FURTHER DILUTION IN 50 mL OF A COMPATIBLE SOLUTION AND INFUSED INTRAVENOUSLY.

    A Pharmacy Bulk Package is a container of a sterile preparation for intravenous use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion.

    The molecular formula is C14H13N8NaO4S3. The molecular weight is 476.49.

    The structural formula is as follows:

    Structural Formula

    The pH of the reconstituted solution is between 4 and 6.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Cefazolin is an antibacterial drug [see Microbiology (12.4)].

    12.2 Pharmacodynamics

    The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients.

    12.3 Pharmacokinetics

    Studies have shown that following intravenous administration of cefazolin to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose.

    The serum half-life for cefazolin is approximately 1.8 hours following IV administration.

    In a study, using normal volunteers, of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg), cefazolin produced a steady serum level at the third hour of approximately 28 mcg/mL.

    Plasma pharmacokinetic parameters of cefazolin in normal volunteers (N=12) following a single 15-minute intravenous infusion of 2 grams of Cefazolin for Injection, USP are summarized in Table 3.

    Table 3: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Normal Volunteers

    *Tmax reported as median( range)

    N = number of subjects observed; Cmax = maximum plasma concentration; Tmax = time to maximum plasma concentration; AUC0-inf = area under the plasma concentration-time curve extrapolated to infinity; t½ = apparent plasma terminal elimination half-life; CL = total clearance; Vz = volume of distribution
    NCmax
    (mcg/mL)    		Tmax*
    (h)    		AUC0-inf
    (mcg*h/mL)    		t½
    (h)    		CL
    (L/h)    		Vz
    (L)
    Single 2 g Dose as a 15-Minute I.V. Infusion12280.9
    (45.9)    		0.25
    (0.25-0.33)    		509.9 (89.3)2.01 (0.28)4.03 (0.68)11.5 (1.53)

    Studies in patients hospitalized with infections indicate that cefazolin produces mean peak serum levels approximately equivalent to those seen in normal volunteers.

    Bile levels in patients without obstructive biliary disease can reach or exceed serum levels by up to five times; however, in patients with obstructive biliary disease, bile levels of cefazolin are considerably lower than serum levels (< 1.0 mcg/mL).

    In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.

    Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers.

    Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.

    12.4 Microbiology

    Mechanism of Action

    Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.

    Resistance

    Predominant mechanisms of bacterial resistance to cephalosporins include the presence of extended-spectrum beta-lactamases and enzymatic hydrolysis.

    Antimicrobial Activity

    Cefazolin has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE (1) section.

    • Gram-Positive Bacteria
      • Staphylococcus aureus
      • Staphylococcus epidermidis
      • Streptococcus agalactiae
      • Streptococcus pneumoniae
      • Streptococcus pyogenes

    Methicillin-resistant staphylococci are uniformly resistant to cefazolin,

    • Gram-Negative Bacteria
      • Escherichia coli
      • Proteus mirabilis

    Most isolates of indole positive Proteus (Proteus vulgaris), Enterobacter spp., Morganella morganii, Providencia rettgeri, Serratia spp. and Pseudomonas spp. are resistant to cefazolin.

    Susceptibility Testing

    For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin for Injection, USP have not been performed.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Cefazolin for Injection, USP, is available in the following SmartPak® Pharmacy Bulk Packages bags:

    100 grams* One Pharmacy Bulk Package bag Product No. 1100 NDC: 66288-1100-1

    300 grams** One Pharmacy Bulk Package bag Product No. 1300 NDC: 66288-1300-1

    *Each 100 gram Pharmacy Bulk Package bag contains sterile cefazolin sodium equivalent to 100 grams of cefazolin.

    **Each 300 gram Pharmacy Bulk Package bag contains sterile cefazolin sodium equivalent to 300 grams of cefazolin.

    SmartPak® system components are not made with natural rubber latex.

    As with other cephalosporins, cefazolin tends to darken depending on storage conditions within the stated recommendations; however, product potency is not adversely affected.

    Storage Conditions

    Prior to reconstitution, store dry powder at 20° to 25° C (68° to77° F). [See USP Controlled Room Temperature]. Protect From Light.

  • 17 PATIENT COUNSELING INFORMATION

    Patients should be advised that allergic reactions, including serious allergic reactions could occur and that serious reactions require immediate treatment and discontinuation of cefazolin. Patients should report to their health care provider any previous allergic reactions to cefazolin, cephalosporins, penicillins or other similar antibacterials.

    Patients should be advised that diarrhea is a common problem caused by antibiotics, which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterials. If this occurs, patients should contact a physician as soon as possible.

    Patients should be counseled that antibacterial drugs including cefazolin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefazolin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefazolin or other antibacterial drugs in the future.

    Rx only
    SmartPak is a registered trademark of Samson Medical Technologies, L.L.C.
    Clinitest is a registered trademark of Siemens Medical Solutions Diagnostics.
    Clinistix is a registered trademark of Bayer Healthcare LLC.

    C1100i

    Manufactured for

    ​SAMSON MEDICAL TECHNOLOGIES, L.L.C.

    Cherry Hill, NJ 08003

    by

    ACS Dobfar S.p.A.

    20067 Tribiano (Milano) Italy

  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel – 100 g Inner Bag Label

    NDC: 66288-1100-1 SMARTPAK®

    CEFAZOLIN For Injection, USP

    PHARMACY BULK PACKAGE
    NOT FOR DIRECT INFUSION

    100 grams [ONE HUNDRED GRAMS] per Pharmacy Bulk Package Bag

    FOR INTRAVENOUS USE ONLY

    NOT TO BE DISPENSED AS A UNIT

    Rx Only

    Principal Display Panel – 100 g Inner Bag Label
  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel – 100 g Outer Bag Label

    NDC: 66288-1100-1 SMARTPAK®

    CEFAZOLIN For Injection, USP

    PHARMACY BULK PACKAGE
    NOT FOR DIRECT INFUSION

    100 grams [ONE HUNDRED GRAMS] per Pharmacy Bulk Package Bag

    FOR INTRAVENOUS USE ONLY

    NOT TO BE DISPENSED AS A UNIT

    Rx Only

    Principal Display Panel – 100 g Outer Bag Label
  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel – 300 g Inner Bag Label

    NDC: 66288-1300-1 SMARTPAK®

    CEFAZOLIN For Injection, USP

    PHARMACY BULK PACKAGE

    NOT FOR DIRECT INFUSION

    300 grams [THREE HUNDRED GRAMS] per Pharmacy Bulk Package Bag

    FOR INTRAVENOUS USE ONLY

    NOT TO BE DISPENSED AS A UNIT

    Rx Only

    Principal Display Panel – 300 g Inner Bag Label
  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel – 300 g Outer Bag Label

    NDC: 66288-1300-1 SMARTPAK®

    CEFAZOLIN For Injection, USP

    PHARMACY BULK PACKAGE

    NOT FOR DIRECT INFUSION

    300 grams [THREE HUNDRED GRAMS] per Pharmacy Bulk Package Bag

    FOR INTRAVENOUS USE ONLY

    NOT TO BE DISPENSED AS A UNIT

    Rx Only

    Principal Display Panel – 300 g Outer Bag Label
  • INGREDIENTS AND APPEARANCE
    CEFAZOLIN 
    cefazolin sodium injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 66288-1100
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Cefazolin Sodium (UNII: P380M0454Z) (Cefazolin - UNII:IHS69L0Y4T) Cefazolin100 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 66288-1100-11 in 1 BAG; Type 0: Not a Combination Product01/01/2007
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06514101/01/2007
    CEFAZOLIN 
    cefazolin sodium injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 66288-1300
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Cefazolin Sodium (UNII: P380M0454Z) (Cefazolin - UNII:IHS69L0Y4T) Cefazolin300 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 66288-1300-11 in 1 BAG; Type 0: Not a Combination Product01/01/2007
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06514101/01/2007
    Labeler - Samson Medical Technologies, L.L.C. (102837429)
    Establishment
    NameAddressID/FEIBusiness Operations
    ACS Dobfar S.p.A.429243025MANUFACTURE(66288-1100, 66288-1300)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.